Is Pure, High Dose, CBD Ready for the Prescription Pad?Is Pure, High Dose, CBD Ready for the Prescription Pad?
Addiction Medicine Made Easy
Dr Casey Grover talks with Pulak Sharma and Dr Marwaha about pure, high-dose prescription CBD, its safety profile, and how they are using it for pain, anxiety and addiction-related issues. The conversation focuses on evidence, cautious clinical practice, and whether CBD deserves a place alongside established treatments.
35:46•5 Oct 2026
High-Dose Pure CBD: A Sceptical Doctor’s Deep Dive into a New Pain and Anxiety Tool
Episode Overview
- Pure, high-dose CBD without THC may offer a safer option for anxiety and chronic pain than many commonly used medications.
- Prescription-grade CBD from a compounding pharmacy allows clear dosing, quality control, and monitoring, unlike over-the-counter supplements.
- High-dose CBD is being used as an adjunct to reduce reliance on NSAIDs, muscle relaxants, gabapentin, benzodiazepines, and some substances such as alcohol and tobacco.
- Early experience suggests CBD can be particularly useful in elderly patients who have limited pain-management options and high risk of side effects.
- Kazmira Therapeutics is collecting clinical data via telemedicine to support future insurance coverage and broader acceptance of prescription CBD.
“I feel, honest to God, more confident prescribing this than the current standard of care for a lot of these conditions.”
How do different strategies aid in addiction recovery? This episode of *Addiction Medicine Made Easy* zeroes in on one substance that often sits in a grey area: CBD. Emergency physician–turned–addiction specialist Dr Casey Grover talks with Pulak Sharma, founder and CEO of Kazmira Therapeutics, and internal medicine doctor Dr Marwaha about whether pure, high‑dose CBD is ready to be treated like a real prescription medicine. Dr Grover starts from a place many clinicians will relate to: deep scepticism.
He’s seen cannabis use disorder up close, worries about contaminated supplements, and jokes about “code cannabis” visits where older patients accidentally overdose on THC edibles. That’s why Pulak’s claim that “cbd is not a controlled substance” and that their product has “zero thc” grabs attention. Pulak explains how Kazmira set up a 503a compounding pharmacy to produce prescription‑grade CBD as an active pharmaceutical ingredient, aiming for purity far beyond standard supplements and even beyond the seizure drug Epidiolex.
Their goal is clear dosing, no THC, and a telemedicine model that keeps cost and access in mind while they gather real‑world data. Dr Marwaha brings the clinical angle, describing how he uses high‑dose CBD (300–400 mg, far above most shop‑bought products) for generalised anxiety, PTSD, chronic pain, and even supporting patients with alcohol and tobacco use issues.
He calls it “a safer, mild downer” and says he feels “more confident prescribing this than the current standard of care” in many situations, especially for elderly patients who can’t tolerate NSAIDs, muscle relaxants, or gabapentin. You’ll hear candid talk about benzos, opioids, cannabis hyperemesis, and the grind of treating pain and anxiety without causing more harm.
If you’re curious about where CBD might fit into modern addiction medicine and acute care, this conversation offers a grounded, sceptic‑friendly look at a plant‑based option that’s trying to earn its place on the prescription pad. Could pure, high‑dose CBD become a useful tool in your recovery toolkit or clinical practice?
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.